NasdaqCM:AMRNBiotechs
Amarin (AMRN) Trailing Losses Narrow To US$38.8 Million Challenging Bearish Narratives
Amarin's FY 2025 Results Put Losses and Margins Back in Focus
Amarin (AMRN) has just closed out FY 2025 with Q4 revenue of US$49.2 million and a basic EPS loss of US$0.06, capping a year where the trailing twelve month figures show US$213.6 million of revenue and a cumulative EPS loss of US$1.87. Over recent periods the company has seen quarterly revenue move between US$42.0 million and US$72.7 million while basic EPS swung from a loss of US$0.06 to a loss of US$0.76, leaving investors...